Chapmans to take strategic stake in medicinal cannabis group, MJ Life Sciences

By Trevor Hoey. Published at Aug 30, 2017, in Small Caps

Diversified investment group, Chapmans (ASX:CHP) announced on Tuesday that it had entered into a binding Heads of Agreement (HOA) with MJ Life Sciences (MJLS) with a view to making a strategic investment of $500,000 in MJLS, an Australian special-purpose company established with the aim of becoming a leading global medicinal cannabis holding and investment company.

MJLS is a direct investor in Caziwell Inc., owner of the established North American medicinal cannabis brand and business, Aunt Zelda’s, with convertible note rights of up to 49.99% in Caziwell Inc.

As a company targeting high growth investments, MJLS ticks the boxes for Chapmans. Under the terms of the Heads of Agreement, CHP will acquire a 50% holding in the issued capital of MJLS and will have equal board representation.

CHP also said that subsequent to the completion of the initial investment it would seek to make further investments in MJLS to support its investment goals. Management expects to complete due diligence within the next 30 days.

This initiative replaces the company’s previously announced proposed investment in the Aunt Zelda’s medicinal cannabis business as this will not be proceeding. Management sees a direct investment in MJLS as providing a superior opportunity with better strategic advantages and the prospect of strong shareholder returns.

As it is early stages in this deal and as its Aunt Zelda deal fell over, it is important for investors to seek professional financial advice before making an investment decision in this stock.

MJLS is owned by three of the leading principals in the rapidly expanding Australian and global medicinal cannabis sector, Harry Karelis, Jason Peterson and Dr Stewart Washer.

These three executives have strong operational and transactional experience in the medicinal cannabis sector and are founders and directors of ASX-listed medicinal cannabis sector companies, Auscann Group Holdings (ASX: AC8) and Zelda Therapeutics (ASX: ZLD).


Where to invest $1,000 right now

When the experts at Next Investors have a stock pick, it may pay to listen.

The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.

They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.

Click the link below to see what they are currently investing in.


SEE THE PORTFOLIO

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X